Retraction Note: Lixisenatide protects doxorubicin-induced renal fibrosis by activating \( \text{NF-}\kappa\text{B}/\text{TNF-}\alpha \) and \( \text{TGF-}\beta/\text{Smad} \) pathways

N.-F. GUO, Y.-J. CAO, X. CHEN, Y. ZHANG, Y.-P. FAN, J. LIU, X.-L. CHEN

Department of Nephrology, the Affiliated Hospital of Nantong University, Nantong, China

The article “Lixisenatide protects doxorubicin-induced renal fibrosis by activating wNF-\( \kappa \)B/TNF-\( \alpha \) and TGF-\( \beta \)/Smad pathways”, by N.-F. Guo, Y.-J. Cao, X. Chen, Y. Zhang, Y.-P. Fan, J. Liu, X.-L. Chen published in Eur Rev Med Pharmacol Sci 2019; 23 (9): 4017-4026. DOI: 10.26355/eurrev_201905_17832–PMID: 31115031 has been retracted by the Editor in Chief for the following reasons:

This paper has been questioned on PubPeer (https://pubpeer.com/publications/983F02C9C18817139AE18497C359FA). In particular, concerns were raised about Figures 2A and 5A as the figures result to overlap with previously published papers.

The Editorial Office has contacted the corresponding author of the article to provide a reply to the comments on PubPeer and check the raw data. Still, the journal has yet to receive a reply. Therefore, considering the comments released on PubPeer and the lack of response from authors, the Editor in Chief no longer relies on the data presented and decided to withdraw the manuscript.

The Publisher apologizes for any inconvenience this may cause.